Patients may receive the first 3 vaccines as long as they are stable and remain eligible. Subsequently, f or the purpose of this study, progression will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology (when previously negative), or radiographic progression as defined by protocol criteria. Following surgery and leukapheresis, adequate organ function testing will be repeated prior to initiation of cyclophosphamide and fludarabine conditioning. Drug administration and dosage for the lymphodepletive conditioning may be adjusted ba sed upon hematologic performance and organ function testing results. After completion of salvage chemotherapy and starting 11 days before immunotherapy, patients will receive NMA chemotherapy which includes 2 days of cyclophosphamide IV followed by 5 day s of fludarabine IV. Approximately 72 hours following fludarabine, PBSCs , if available, will be infused. Approximately 96 hours following the final dose of fludarabine, Immunotherapy begins with infusion of TTRNA -xALT (3x107/kg) and injection of the first TTRNA -DC (1x107cells) vaccine. The NMA recovery will incorporate G -CSF at 5 microgram/kg/day beginning no later than Day 16 until ANC recovers to >1000 cells as presented below: Drug Name Route Dose Schedule Temozolomide PO 150 mg/m2/day Days 1-5 Etoposide PO 30 mg/m2/day Days 1-14 Filgrastim (G -CSF) SQ or IV 10 micrograms/ kg/day Starting Day 15 *administered each cycle until enough CD34 cells are harvested ( goal of 2x10 6/kg) for infusion Re-MATC H Protocol Page 46 of 106 Version: 20180628 Drug Name Route Dose Schedule Instructions for administration Cyclophosphamide IV 1000 mg/m2/day Days 1 & 2 Dose reduce or omit based on cardiac and/or pulmonary function Fludarabine IV 25 mg/m2/day Days 3 -7 Dose reduce or omit based on creatinine clearance Peripheral Blood Stem Cells , if available IV A minimum of 2x106 CD34+ cells/kg or all available cells if < 2x10 6 CD34+ cells/kg Day 10 IV through central venous catheter per institutional guidelines TTRNA -xALT IV 3x107/kg Day 11 IV over 10-30 minutes through central venous catheter . Pre-medicate 30 -60 minutes p rior to infusion with acetaminophen ( up to 10- 15 mg/kg/dose) and Benadryl ( up to 1 mg/kg) to reduce infusion -related reactions.